Scenario: Patient on MBMDT (leprosy treatment) develops inflammation over existing skin lesions + nerve involvement.
Diagnosis: Type 1 Lepra Reaction (Reversal Reaction)
- Mechanism: Abrupt increase in cell-mediated immunity (CMI) against Mycobacterium leprae
- Features: Erythema, edema, warmth of pre-existing plaques; nerve tenderness; new ulcerations
- Most common in borderline leprosy subtypes (BT, BB, BL)
Golden rule in lepra reactions: ALT/MDT is NEVER stopped during a reaction -- stopping increases bacterial load.
Management of Type 1 reaction:
- Continue ALT (MDT)
- Add corticosteroids (prednisolone 40-60 mg/day, tapered over weeks)
- Steroids prevent irreversible nerve damage
Note on thalidomide: Thalidomide is used for Type 2 (ENL) reactions, not Type 1.
\[\boxed{\text{Continue ALT and start steroids}}\]